|
Online View
|
|
|
|
Organoids to Become the Cornerstone of Modern Drug Development
|
|
|
|
On April 10, 2025, the U.S. FDA announced a groundbreaking policy to phase out animal testing requirements in drug development, starting with monoclonal antibodies and other biologics. Laboratory-grown human “organoids” and organ-on-a-chip systems are emerging as preferred New Approach Methodologies (NAMs) , recognized for their human biological accuracy and disease modeling capabilities. Sino Biological supports this transition by providing essential tools, including organoid culture cytokines, samll molecules, and biomarker characterization antibodies, covering a wide range of physiological and tumor models, bridging research and clinical application gaps.
|
|
Click to Learn More about 3D Organoids Research Solutions >>>
|
Product Validation Results
|
|
Human EGF
（Cat#: 10605-HNAE）
|
|
High purity and SEC-HPLC verified
|
|
≥ 95% as determined by SDS-PAGE and SEC-HPLC.
|
|
Industry-leading activity
|
|
Measured in a cell proliferation assay using
Balb/C 3T3 mouse embryonic fibroblasts.
|
|
|
Human EGF Used for Human Fetal Thyroid Organoids Culture
|
|
|
More Products for Organoids Research
|
|
|
|
View More Organoids Research Products > > >
|
Download Organoids Guide
|
|
|
|
|
|
Don’t Miss Out!
|
|
|
|
Kinase Drug Discovery Solutions >> |
|
Center for Bioprocessing (C4B)
US-Based Recombinant Production >>
|
|
|
|
|
|
|
|
